Differential mRNA expression levels of human histone-modifying enzymes in normal karyotype B cell pediatric acute lymphoblastic leukemia

International Journal of Molecular Sciences

Volumn 14, Issue 2, 2013, Pages 3376-3394

  Tao, Yan Fang ^a   Li, Pang ^a   Du, Xiao Juan ^b   Sun, Li Chao ^c   Hu, Shao Yan ^a   Lu, Jun ^a   Cao, Lan ^a   Zhao, Wen Li ^a   Feng, Xing ^a   Wang, Jian ^a   Wu, Dong ^a   Wang, Na ^a   Ni, Jian ^d   Pan, Jian ^a  

^a CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b The 5th Hospital of Chinese PLA   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Histone modifying enzymes; Pediatric acute lymphoblastic leukemia; Real time PCR array

Indexed keywords

CURCUMIN; DNA; DNA METHYLTRANSFERASE; GENOMIC DNA; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE H3; MESSENGER RNA; MICRORNA 34A;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; CHILD; CONTROLLED STUDY; DNA RECOMBINATION; DNA REPAIR; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HISTONE PHOSPHORYLATION; HISTONE UBIQUITINATION; HUMAN; KARYOTYPE; MALE; MOLECULAR MECHANICS; MONONUCLEAR CELL; PEDIATRICS; PRESCHOOL CHILD; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84875099294     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14023376     Document Type: Article

References (54)

1. Foa, R. Acute lymphoblastic leukemia: Age and biology. Pediatr. Rep. 2011, 3, e2.
2. Krupa, M.; Szczepanski, T. Prophylaxis of hepatitis B in children treated for ALL. Wiad. Lek. 2009, 62, 149-152.
3. Pui, C.H. Acute lymphoblastic leukemia: Introduction. Semin. Hematol. 2009, 46, 1-2.
4. Salek, C.; Sponerova, D.; Soukupova Maaloufova, J. Acute lymphoblastic leukemia: Past and present. Vnitr. Lek. 2012, 58, 20-26.
5. Zangrando, A.; Dell'orto, M.C.; Te Kronnie, G.; Basso, G. MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures. BMC Med. Genomics 2009, 2, 36.
6. Mishra, B.P.; Ansari, K.I.; Mandal, S.S. Dynamic association of MLL1, H3K4 trimethylation with chromatin and Hox gene expression during the cell cycle. FEBS J. 2009, 276, 1629-1640.
7. Passaro, D.; Rana, G.; Piscopo, M.; Viggiano, E.; de Luca, B.; Fucci, L. Epigenetic chromatin modifications in the cortical spreading depression. Brain Res. 2010, 1329, 1-9.
8. Krivtsov, A.V.; Armstrong, S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 2007, 7, 823-833.
9. Cosgrove, M.S.; Patel, A. Mixed lineage leukemia: A structure-function perspective of the MLL1 protein. FEBS J. 2010, 277, 1832-1842.
10. Islam, A.B.; Richter, W.F.; Jacobs, L.A.; Lopez-Bigas, N.; Benevolenskaya, E.V. Co-regulation of histone-modifying enzymes in cancer. PLoS One 2011, 6, e24023.
11. Fullgrabe, J.; Kavanagh, E.; Joseph, B. Histone onco-modifications. Oncogene 2011, 30, 3391-3403.
12. Henrique, R.; Luis, A.S.; Jeronimo, C. The epigenetics of renal cell tumors: From biology to biomarkers. Front. Genet. 2012, 3, 94.
13. Nemeth, A.; Langst, G. Chromatin higher order structure: Opening up chromatin for transcription. Brief Funct. Genomic Proteomic 2004, 2, 334-343.
14. Zhang, Y.; Moriguchi, H. Chromatin remodeling system, cancer stem-like attractors, and cellular reprogramming. Cell. Mol. Life Sci 2011, 68, 3557-3571.
15. Del Rizzo, P.A.; Trievel, R.C. Substrate and product specificities of SET domain methyltransferases. Epigenetics 2011, 6, 1059-1067.
16. Albaugh, B.N.; Arnold, K.M.; Denu, J.M. KAT(ching) metabolism by the tail: Insight into the links between lysine acetyltransferases and metabolism. Chembiochem 2011, 12, 290-298.
17. Hou, H.; Yu, H. Structural insights into histone lysine demethylation. Curr. Opin. Struct. Biol. 2010, 20, 739-748.
18. Krichevsky, A.; Zaltsman, A.; Lacroix, B.; Citovsky, V. Involvement of KDM1C histone demethylase-OTLD1 otubain-like histone deubiquitinase complexes in plant gene repression. Proc. Natl. Acad. Sci. USA 2011, 108, 11157-11162.
19. Luo, X.; Liu, Y.; Kubicek, S.; Myllyharju, J.; Tumber, A.; Ng, S.; Che, K.H.; Podoll, J.; Heightman, T.D.; Oppermann, U.; et al. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. J. Am. Chem. Soc. 2011, 133, 9451-9456.
20. Marmorstein, R.; Trievel, R.C. Histone modifying enzymes: Structures, mechanisms, and specificities. Biochim. Biophys. Acta 2009, 1789, 58-68.
21. Upadhyay, A.K.; Cheng, X. Dynamics of histone lysine methylation: Structures of methyl writers and erasers. Prog. Drug Res. 2011, 67, 107-124.
22. Lawless, M.W.; Norris, S.; O'Byrne, K.J.; Gray, S.G. Targeting histone deacetylases for the treatment of disease. J. Cell. Mol. Med. 2009, 13, 826-852.
23. Tao, Y.F.; Wu, D.; Pang, L.; Zhao, W.L.; Lu, J.; Wang, N.; Wang, J.; Feng, X.; Li, Y.H.; Ni, J.; et al. Analyzing the gene expression profile of pediatric acute myeloid leukemia with real-time PCR arrays. Cancer Cell. Int. 2012, 12, 40.
24. Arikawa, E.; Sun, Y.; Wang, J.; Zhou, Q.; Ning, B.; Dial, S.L.; Guo, L.; Yang, J. Cross-platform comparison of SYBR Green real-time PCR with TaqMan PCR, microarrays and other gene expression measurement technologies evaluated in the MicroArray Quality Control (MAQC) study. BMC Genomics 2008, 9, 328.
25. Moreno, D.A.; Scrideli, C.A.; Cortez, M.A.; de Paula Queiroz, R.; Valera, E.T.; da Silva Silveira, V.; Yunes, J.A.; Brandalise, S.R.; Tone, L.G. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 2010, 150, 665-673.
26. Niegisch, G.; Knievel, J.; Koch, A.; Hader, C.; Fischer, U.; Albers, P.; Schulz, W.A. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol. Oncol. 2012, [Epub ahead of print].
27. Patani, N.; Jiang, W.G.; Newbold, R.F.; Mokbel, K. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Res. 2011, 31, 4115-4125.
28. Noh, J.H.; Jung, K.H.; Kim, J.K.; Eun, J.W.; Bae, H.J.; Xie, H.J.; Chang, Y.G.; Kim, M.G.; Park, W.S.; Lee, J.Y.; et al. Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One 2011, 6, e28103.
29. Zhu, P.; Martin, E.; Mengwasser, J.; Schlag, P.; Janssen, K.P.; Gottlicher, M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004, 5, 455-463.
30. Zhu, G.; Wang, Y.; Huang, B.; Liang, J.; Ding, Y.; Xu, A.; Wu, W. A Rac1/PAK1 cascade controls beta-catenin activation in colon cancer cells. Oncogene 2012, 31, 1001-1012.
31. Lee, M.Y.; Kim, S.H.; Ihm, H.J.; Chae, H.D.; Kim, C.H.; Kang, B.M. Up-regulation of p21-activated kinase 1 by in vitro treatment with interleukin 1-beta and its increased expression in ovarian endometriotic cysts. Fertil Steril 2011, 96, 508-511.
32. Kamai, T.; Shirataki, H.; Nakanishi, K.; Furuya, N.; Kambara, T.; Abe, H.; Oyama, T.; Yoshida, K. Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer. BMC Cancer 2010, 10, 164.
33. Kim, S.R.; Kim, S.H.; Lee, H.W.; Chae, H.D.; Kim, C.H.; Kang, B.M. Increased expression of p21-activated kinase in adenomyosis. Fertil Steril 2010, 94, 1125-1128.
34. Wang, R.A.; Vadlamudi, R.K.; Bagheri-Yarmand, R.; Beuvink, I.; Hynes, N.E.; Kumar, R. Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands. J. Cell. Biol. 2003, 161, 583-592.
35. Akinmade, D.; Talukder, A.H.; Zhang, Y.; Luo, W.M.; Kumar, R.; Hamburger, A.W. Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells. Br. J. Cancer 2008, 98, 1132-1140.
36. Siu, M.K.; Wong, E.S.; Chan, H.Y.; Kong, D.S.; Woo, N.W.; Tam, K.F.; Ngan, H.Y.; Chan, Q.K.; Chan, D.C.; Chan, K.Y.; et al. Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: Effects on prognosis and cell invasion. Int. J. Cancer 2010, 127, 21-31.
37. Tharakan, R.; Lepont, P.; Singleton, D.; Kumar, R.; Khan, S. Phosphorylation of estrogen receptor alpha, serine residue 305 enhances activity. Mol. Cell. Endocrinol. 2008, 295, 70-78.
38. Wang, J.X.; Zhou, Y.N.; Zou, S.J.; Ren, T.W.; Zhang, Z.Y. Correlations of P21-activated kinase 1 expression to clinicopathological features of gastric carcinoma and patients' prognosis. Chin. J. Cancer 2010, 29, 649-654.
39. Liu, F.; Li, X.; Wang, C.; Cai, X.; Du, Z.; Xu, H.; Li, F. Downregulation of p21-activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1. Int. J. Cancer 2009, 125, 2511-2519.
40. Tillinghast, G.W.; Partee, J.; Albert, P.; Kelley, J.M.; Burtow, K.H.; Kelly, K. Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines. Genes Chromosomes Cancer 2003, 37, 121-131.
41. Bryan, E.J.; Jokubaitis, V.J.; Chamberlain, N.L.; Baxter, S.W.; Dawson, E.; Choong, D.Y.; Campbell, I.G. Mutation analysis of EP300 in colon, breast and ovarian carcinomas. Int. J. Cancer 2002, 102, 137-141.
42. Gayther, S.A.; Batley, S.J.; Linger, L.; Bannister, A.; Thorpe, K.; Chin, S.F.; Daigo, Y.; Russell, P.; Wilson, A.; Sowter, H.M.; et al. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 2000, 24, 300-303.
43. Zhong, J.; Cao, R.X.; Zu, X.Y.; Hong, T.; Yang, J.; Liu, L.; Xiao, X.H.; Ding, W.J.; Zhao, Q.; Liu, J.H.; et al. Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma. FEBS J. 2012, 279, 316-335.
44. Hata, K.; Nishijima, K.; Mizuguchi, J. Role for Btg1 and Btg2 in growth arrest of WEHI-231 cells through arginine methylation following membrane immunoglobulin engagement. Exp. Cell. Res. 2007, 313, 2356-2366.
45. Scoumanne, A.; Chen, X. The epithelial cell transforming sequence 2, a guanine nucleotide exchange factor for Rho GTPases, is repressed by p53 via protein methyltransferases and is required for G1-S transition. Cancer Res. 2006, 66, 6271-6279.
46. Ganesh, L.; Yoshimoto, T.; Moorthy, N.C.; Akahata, W.; Boehm, M.; Nabel, E.G.; Nabel, G.J. Protein methyltransferase 2 inhibits NF-kappaB function and promotes apoptosis. Mol. Cell. Biol. 2006, 26, 3864-3874.
47. Wong, K.Y.; Yu, L.; Chim, C.S. DNA methylation of tumor suppressor miRNA genes: A lesson from the miR-34 family. Epigenomics 2011, 3, 83-92.
48. Hermeking, H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010, 17, 193-199.
49. Tabuchi, T.; Satoh, M.; Itoh, T.; Nakamura, M. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: Effect of statins on SIRT1 and microRNA-34a expression. Clin. Sci. 2012, 123, 161-171.
50. Yamakuchi, M.; Lowenstein, C.J. MiR-34, SIRT1 and p53: The feedback loop. Cell Cycle 2009, 8, 712-715.
51. Yamakuchi, M.; Ferlito, M.; Lowenstein, C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. USA 2008, 105, 13421-13426.
52. Shishodia, S. Molecular mechanisms of curcumin action: Gene expression. Biofactors 2012, doi:10.1002/biof.1041.
53. Basnet, P.; Skalko-Basnet, N. Curcumin: An anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 2011, 16, 4567-4598.
54. Ravindran, J.; Prasad, S.; Aggarwal, B.B. Curcumin and cancer cells: How many ways can curry kill tumor cells selectively? AAPS J. 2009, 11, 495-510.